medigraphic.com
Colegio de Medicina Interna de México.

2021, Number 3

<< Back Next >>

Med Int Mex 2021; 37 (3)

Ambulatory treatment with chloroquine in patients with suspicion of COVID-19 for the reduction of symptoms associated to the infection

Lugo-Zamudio G, Navarrete-Martínez LB, Hernández-Salazar C, Reyes-Rodríguez FG, Guerrero-Beltrán L, Arellano-Álvarez DS

Language: Spanish
References: 24
Page: 359-365
PDF size: 211.82 Kb.


ABSTRACT

Objective: To establish whether there is clinical improvement with the administration of chloroquine as outpatient treatment in patients suspected of COVID-19 assessed by the reduction of clinical manifestations associated with viral infection.
Materials and Methods: An experimental study was made in patients suspected of COVID-19 who were attended in the respiratory emergency service of the Hospital Juárez de México from June 1st to July 30th, 2020, who received outpatient treatment with chloroquine. The patients were followed up by telephone to find out their health condition.
Results: Fifty patients were included, of which 36 were female. The mean age was 41.1 year; the most frequent symptoms were fever, cough and odynophagia; the most persistent symptom was cough (31 out of 50). Also, 24 patients were positive for SARS-CoV-2 and completed their treatment with chloroquine, with persistent descricough; diarrhea, dysgeusia, and symptoms such as nausea, hypogeusia and headache were documented. No patient required a second evaluation in the emergency room or hospital admissions.
Conclusions: Clinical evidence suggests that chloroquine may be useful in reducing the symptoms associated with SARS-CoV-2 if it is administered in the first five days of the onset of the disease; controlled studies are required to confirm this possibility.


REFERENCES

  1. Wuhan seafood market pneumonia in virus isolate Wuhan- Hu, complete genome, 23 de enero de 2020: http://www. nim.nih.gov/nuccore/MN908947.3.

  2. Sorbello M, El‐Boghdadly K, Di Giacinto I, Cataldo R, et al. The Italian coronavirus disease 2019 outbreak: recommendations from clinical practice. Anaesthesia 2020; 75 (6): 724-732. doi: 10.1111/anae.15049.

  3. Zhang JJ, Dong X, Cao YY, Yuan Y, et al. Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China. Allergy 2020. https://doi.org/10.1111/all.14238.

  4. Cruz MP, Santos E, Cervantes MV, Juárez ML. COVID-19, una emergencia de salud pública mundial. Rev Clín Esp 2021; 221 (1): 55-61. doi: 10.1016/j.rce.2020.03.001.

  5. Silva-Rojas GA, Farfán-Cano GG, Silva-Rojas KJ, Espin-Bayona DA, et al. COVID-19 chloroquine and/or hydroxychloroquine prophylaxis? 2020. http://dx.doi.org/10.13140/ RG.2.2.14036.14728/1.

  6. Zhu N, Zhang D, Wang W, Li X, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382: 727-733. doi: 10.1056/NEJMoa2001017.

  7. Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes: Knowledge in progress. Diabetes Res Clin Pract 2020; 162: 108142. doi: 10.1016/j.diabres. 2020.108142.

  8. Información científico-técnica: Enfermedad por coronavirus, COVID-19. [Internet]. Centro de Coordinación de Alertas y Emergencias Sanitarias. Ministerio de Sanidad, España; abril 20202. Disponible en: https://www.mscbs. gob.es/profesionales/saludPublica/ccayes/alertasActual/ nCov-China/documentos/20200417_ITCoronavirus.pdf.

  9. Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, et al. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care 2020; 57: 279- 283. doi: 10.1016/j.jcrc.2020.03.005.

  10. Grein J, Ohmagari N, Shin D, Diaz G, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 2020; 382: 2327-2336. doi: 10.1056/NEJMoa2007016.

  11. Cai Q, Yang M, Liu D, Chen J, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering 2020; 6 (10): 1192-1198. doi: 10.1016/j. eng.2020.03.007.

  12. Shen C, Wang Z, Zhao F, Yang Y, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 2020; 323 (16): 1582-1589. doi:10.1001/ jama.2020.4783.

  13. Roback JD, Guarner J. Convalescent plasma to treat COVID- 19: possibilities and challenges. JAMA 2020; 323 (16): 1561-1562. doi: 10.1001/jama.2020.4940.

  14. Colson P, Rolain JM, Raoult D. Chloroquine for the 2019 novel coronavirus SARS-CoV-2. Int J Antimicrob Agents 2020; 55: 105923. 10.1016/j.ijantimicag.2020.105923.

  15. Al-Bari MAA. Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother 2020; 70 (6): 1608-1621. doi: 10.1093/jac/dkv018.

  16. Lee SJ, Silverman E, Bargman JM. The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nature Rev Nephrol 2011; 7 (12): 718-29. doi: 10.1038/ nrneph.2011.150.

  17. Savarino A, Boelaert JR, Cassone A, Majori G, et al. Effects of chloroquine on viral infections: an old drug against today’s diseases. Lancet Infect Dis 2003; 3 (11): 722-727. http:// dx.doi.org/10.1016/S1473-3099(03)00806-5.

  18. Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet 2003; 361 (9363): 1111-1118. https://doi.org/10.1016/ S0140-6736(03)12888-7.

  19. Jeong JY, Jue DM. Chloroquine inhibits processing of tumor necrosis factor in lipopolysaccharide-stimulated RAW 264.7 macrophages. J Immunol 1997; 158 (10): 4901-4907.

  20. Barlow A, Landolf KM, Barlow B, Yeung SYA, et al. Review of emerging pharmacotherapy for the treatment of coronavirus disease 2019. Pharmacotherapy 2020; 40 (5): 416-437. doi: 10.1002/phar.2398.

  21. Sanofi‐Aventis USLLC. Aralen (Chloroquine phosphate) package insert. Bridgewater, NJ: Sanofi‐Aventis USLLC; 2017.

  22. Tratamientos disponibles para el manejo de la infección respiratoria por SARS-CoV-2 [Internet]. Agencia Española de Medicamentos y Productos Sanitarios Abril 2020. Disponible en: https://www.aemps.gob.es/la-aemps/ ultima-informacion-de-la-aemps-acerca-del-covid‑19/ tratamientos-disponibles-para-el-manejo-de-la-infeccionrespiratoria- por-sars-cov-2/.

  23. Machado JE, Cárdenas ML, Rodríguez MDL Farmacompendio: Dosificaciones adultas y pediátricas (2a edición). Editorial CELSUS, 2016.

  24. Gallardo E, Costa J, Sallés M, Olivé A. Ageusia por sulfato de cloroquina. Rev Esp Reumatol 2003; 30 (3): 144-144.




2020     |     www.medigraphic.com